CSI Market
Sign In | Register

Sutro Biopharma Inc (STRO) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access STRO quarterly Cash Flow →
A period-by-period view of cash flow from Sutro Biopharma Inc to Dec 31 2021 helps clarify how Dec 31 2025's cash position has changed over time.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
12 Months 		(Dec 31 2024) (Dec 31 2023) (Dec 31 2022) (Dec 31 2021)
Operating Activities
Income-191.09
Depreciation & amortization7.32
Amortization of Other Assets0.00
Accretion Expense0.00
Asset Impairment Charges1.69
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets, Total0.00
Share-based Compensation14.01
Income (Loss) from Equity Method Investments0.00
Financial Instruments and Foreign Currency Transaction0.00
Revaluation Of Option Liability-
Revaluation Of Redeemable Convertible Preferred Stock Warrant Liability-
Equity Securities Fv Ni Unrealized Gain Loss-
Increase Decrease In Contract With Customer Liability-69.73
Noncash Lease Expenses5.88
Income taxes0.00
Unrealized Gain (Loss) on Derivatives and Commodity Contracts0.00
Accounts Receivable6.38
Increase (Decrease) in Accounts Payable-2.47
Accrued Expense0.00
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets19.35
Other Working Capital0.00
Other Noncash Income (Expense)0.57
Other net0.00
Payments for (Proceeds from) Other Operating Activities30.85
Discontinued operations0.00
Net Cash flow from Operating Activities-177.23
Investing Activities
Capital Expenditures0.00
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Payments to Acquire Marketable Securities-264.95
Real Estate Investments0.00
Proceeds From Maturities Of Marketable Securities253.77
Proceeds From Sales Of Marketable Securities57.89
Proceeds From Exercise Of Options For Sutrovax Shares-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net-1.70
Discontinued operations0.00
Net Cash Flow from Investing Activities45.01
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.38
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-0.33
Proceeds From Payment Of Note Receivable By Stockholder-
Proceeds Interest From Payment Of Note Receivable By Stockholder-
Proceeds From Preferred Stock Warrants Exercises-
Proceeds From Exercise Of Common Stock Options And Common Stock Warrants-
Proceeds From A Research Development And Commercialization Agreement-
Proceeds From Issuance Of Common Stock Options And Common Stock Warrants-
Payment Of Offering Costs-
Proceeds From Sale Of Future Royalties Net Of Issuance Costs-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities0.04
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-177.23
Total Cash Flow-132.17
4 historic quarters locked

Sign in to unlock the full Sutro Biopharma Inc cash flow history.

Sign In Create Free Account

About Sutro Biopharma Inc Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001193125-26-119873

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document